Trial intelligence / Profile preview

Early prophylactic CD4+ donor lymphocyte infusion after T-cell depleted allogeneic stem cell transplantation

NL-OMON31838Phase 2Active, not recruiting

Sponsor
Leiden University Medical Center
Start
Jul 2008
Modality
Vaccines & Immunotherapeutics, Cell Therapies
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of CD4+ donor lymphocytes in leukemia, myelodysplastic syndrome (MDS), multiple myeloma (MM) and 1 more, sponsored by Leiden University Medical Center. Primary endpoint: Immunological recovery with acceptable GVHD incidence. Started Jul 2008; status: active, not recruiting.

02

Drugs

CD4+ donor lymphocytes
03

Conditions

leukemiamyelodysplastic syndrome (MDS)multiple myeloma (MM)lymphoma

Beyond the preview

Go deeper on NL-OMON31838.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON31838.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call